Objective To provide data regarding prevalence of pediatric Human Immunodeficiency Virus-1 (HIV-1) mucocutaneous manifestations in the era of highly active antiretroviral therapy (HAART). Methods We conducted population-based, prospective, multi-center pediatric HIV-1 surveillance among 276 children with perinatally acquired HIV-1 from 1988– 2009. All CDC category A, B, and C mucocutaneous conditions were evaluated. Results CDC defined HIV-1 related mucocutaneous conditions among the 276 children were: 152, category A; 60, category B; 1, category C. Nearly half (43.4%, [66/152], 35.0% [21/60]) of category A and B diagnoses, respectively occurred in the first year of life, with 59.2% (90/152) and 61.7% (37/60), respectively occurring in the first 2 years of life. The most frequent infectious diagnosis was oropharyngeal thrush (42.4%, [117/276]); the most common inflammatory diagnosis was diaper dermatitis (25.7% [71/276]). There was a temporal decline in prevalence of A and B mucocutaneous diagnoses which was significant for category A: 123, pre-HAART cohort; 29, post-HAART cohort (p< 0.01), and category B: 55, pre-HAART; 5, post-HAART (p<0.01). Conclusions In children with perinatal HIV-1, there was a significant decline in CDC category A and B mucocutaneous diagnoses by temporal cohort, consistent with the introduction of antiretrovirals and HAART. Clinical category A and B mucocutaneous diagnoses were most common in the first 2 years of life, emphasizing the importance of early HIV-1 testing and HAART initiation.
【저자키워드】 Dermatology, skin, mucocutaneous, acquired immunodeficiency syndrome (AIDS), highly active antiretroviral therapy (HAART), Perinatal human immunodeficiency virus (HIV-1),